- Current status
- AHSCT is a standard of care of RRMS
- Wykłady na kursie specjalizacyjnym – transplantologia
- AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.
- CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML
Monthly Archives: January 2015
There is a new publication from prof Burt in JAMA showing improvement of EDSS in MS patients after HSCT. 123 RRMS patients and 28 SPMS patients. http://www.ncbi.nlm.nih.gov/pubmed/25602998 “Outcome analysis was available for 145 patients with a median follow-up of 2 … Continue reading